Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Antibiotic Selection00:57

Antibiotic Selection

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

'Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018-2021-right-to-reply'.

The Journal of antimicrobial chemotherapy·2026
Same author

Mechanisms of fosfomycin resistance observed in clinical isolates of <i>Escherichia coli</i> from Canada: CANWARD 2007-2022.

JAC-antimicrobial resistance·2026
Same author

Enterococcus faecium harbouring vanA, optrA and cfr(D) on a linear plasmid in Canada: a CANWARD surveillance case.

The Journal of antimicrobial chemotherapy·2026
Same author

Rethinking the unmet need for novel antibiotics.

The Journal of antibiotics·2026
Same author

Eravacycline: Data Based on Real Evidence.

The new microbiologica·2025
Same author

Seventeen years of the CANWARD study (2007-23).

The Journal of antimicrobial chemotherapy·2025
Same journal

Monographic Issue on New Concepts in Acute Exacerbations of COPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Bidirectional Clinical Interactions among Exacerbations and Comorbidities in COPD: A Narrative Review.

Seminars in respiratory and critical care medicine·2026
Same journal

Radiological Approach to Severe Respiratory Infections and Pulmonary Complications in Immunocompromised Patients.

Seminars in respiratory and critical care medicine·2026
Same journal

Two Sides of the Same Smoke: Decoding Respiratory Bronchiolitis-Associated Interstitial Lung Disease and Alveolar Macrophage Pneumonia.

Seminars in respiratory and critical care medicine·2026
Same journal

Role of Vaccination in the Prevention of ECOPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Pharmacological Treatment of AECOPD New Perspectives.

Seminars in respiratory and critical care medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Streptococcus pneumoniae: does antimicrobial resistance matter?

Joseph P Lynch1, George G Zhanel

  • 1Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA. jplynch@mednet.ucla.edu

Seminars in Respiratory and Critical Care Medicine
|March 20, 2009
PubMed
Summary
This summary is machine-generated.

Antimicrobial resistance in Streptococcus pneumoniae is a growing global concern, complicating treatment for pneumonia. The clinical impact of this resistance remains unclear due to confounding host and pathogen factors.

More Related Videos

Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP0092
08:53

Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP0092

Published on: October 2, 2017

Related Experiment Videos

Last Updated: Jun 24, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP0092
08:53

Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP0092

Published on: October 2, 2017

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Antimicrobial resistance in Streptococcus pneumoniae, a primary cause of community-acquired pneumonia (CAP), has significantly increased globally over three decades.
  • Penicillin and macrolide resistance, alongside resistance to other antibiotic classes, has escalated, with six international clones driving most resistant isolates.
  • Currently, 15-30% of S. pneumoniae worldwide are multidrug-resistant (MDR), defined as resistance to three or more antibiotic classes.

Purpose of the Study:

  • To review the mechanisms, epidemiology, and clinical impact of antimicrobial resistance in Streptococcus pneumoniae.
  • To explore the challenges in defining the clinical significance of antimicrobial resistance in pneumococcal infections.
  • To discuss strategies for limiting the spread of antimicrobial resistance in this key respiratory pathogen.

Main Methods:

  • Review of existing literature on antimicrobial resistance in Streptococcus pneumoniae.
  • Analysis of epidemiological data on the spread of resistance determinants.
  • Discussion of clinical outcomes and confounding factors influencing treatment failures.

Main Results:

  • While antimicrobial resistance has escalated, its direct clinical impact on treatment outcomes for infections like pneumonia is difficult to establish due to confounding factors.
  • Host factors (age, comorbidities, immunosuppression) and pathogen virulence significantly influence prognosis.
  • Prospective trials to definitively link in vitro resistance to clinical failure are lacking.

Conclusions:

  • The precise clinical impact of antimicrobial resistance in Streptococcus pneumoniae remains challenging to ascertain due to multifactorial influences on patient outcomes.
  • Further research and strategic interventions are needed to address the rising threat of antimicrobial resistance in pneumococcal infections.
  • Understanding resistance mechanisms, spread, and risk factors is crucial for developing effective control strategies.